Licaminlimab is under clinical development by Oculis and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Licaminlimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Licaminlimab overview

Licaminlimab (OCS-02) is under development for the treatment of dry eye and acute anterior uveitis. The therapeutic candidate is a monoclonal antibody applied topically as an ophthalmic solution. The drug is developed based on single-chain antibody fragment technology. It acts by targeting tumor necrosis factor alpha.

Oculis overview

Oculis is a biopharmaceutical company that develops and commercializes topical treatments for acute optic neuritis, chronic back, glaucoma and front-of-the-eye ophthalmic diseases. The company is headquartered in Zug, Switzerland.

For a complete picture of Licaminlimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.